Angels Santé has invested €3.6 million in Byome Labs to commercialize Byome Derma, a pioneering solution for instant skin microbiome measurement, capitalizing on consumer demand for personalized skincare.
Target Information
Byome Labs is an innovative startup that specializes in developing advanced skincare solutions. Recently, it has successfully raised €3.6 million to commercialize its flagship product, Byome Derma. This groundbreaking solution is the first in the world capable of instantly measuring the skin microbiome at retail locations. Byome Derma offers a simple, quick, and painless test that recommends personalized skincare products based on an individual's unique skin microbiome.
The company is led by a talented team that combines scientific rigor with strong business acumen, making them well-equipped to navigate the complexities of the skincare market.
Access Full Deal Insights
You’re viewing a public preview of this deal. To unlock full access to ca. 50,000 other deals in our database and join ca. 400 M&A professionals who are using it daily, sign up for Dealert.
Industry Overview in France
The skincare industry in France is a key component of the country's robust beauty and cosmetics sector. With a strong historical foundation in skincare products and innovations, France has been a leader in setting tren
Similar Deals
Elevation Capital Partners and FoodXpert → Vegetal Food
2024
Angels Santé
invested in
Byome Labs
in 2025
in a Seed Stage deal
Disclosed details
Transaction Size: $4M